AVGO vs LLY: Which Is the Better Buy?

Side-by-side comparison of Broadcom Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-17.
Broadcom Inc. · Technology
$379.86
-41.0% upside to fair value
Grade C High Quality
VS
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction Grade A High Quality
QuantHub Verdict
LLY has more upside to fair value (+31.7%). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric AVGO LLY
Current Price $379.86 $1,179.09
Fair Value Estimate $223.93 $1,552.32
Upside to Fair Value -41.0% +31.7%
Market Cap $1,806.8B $1,110.4B
Forward P/E 61.3x
EV / EBITDA 44.1x 34.3x
Price / Sales 23.9x 14.6x
Price / FCF 55.2x 77.7x
Revenue Growth YoY +47.9% +55.5%
Gross Margin 67.0% 83.5%
Operating Margin 43.7% 45.9%
Return on Equity 36.4% 101.3%
Dividend Yield 0% 0.55%
FCF Yield 1.81% 1.29%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
AVGO — Broadcom Inc.
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a business split nearly evenly between these two segments. The company benefits from a durable competitive moat driven by customer concentration in mission-critical infrastructure, high switching costs, and a broad portfolio spanning semiconductors and infrastructure software. Broadcom h…
LLY — Eli Lilly and Company
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Accumulation Zones
Metric AVGO LLY
Zone Low $167.95 $1,164.24
Zone High $190.34 $1,319.47
In Buy Zone? No Yes
← AVGO Research    LLY Research →    All Research